Newsletter – November 2014
Back to Newsletter Archive | Back to Island Voices
The article below that was published recently in the Times Colonist made my blood boil yet again on this subject, our provincial health care system. The system is seriously flawed. People stand on soapboxes and shout about the evils of two tiered health care systems that benefit the rich to the detriment of the poor. What a load of garbage, we have a two-tiered system now, courtesy of user fees. Prescription charges prevent about 10% of Canadians from using prescriptions issued by their doctors. Basic preventive dental costs, which are set to comply with the coverage offered by insurance companies, are out of reach for a huge number of British Columbians. Ditto eye care, physiotherapy etc. etc.
We need a health care package that covers all preventive general health care services without user fees. Preventive health care is in fact financially cheaper than the subsequent acute and/or chronic care. Without preventive coverage the mental and physical costs to individuals is beyond imagination.
One of the reasons that changes will not happen any time soon is that both federal and provincial politicians who are fixated on reducing taxes, at any costs, have great health care plans.
Roy Summerhayes.
Comment: How we can lower prescription drug costs
Danielle Martin and Steve Morgan / Times Colonist
October 7, 2014 04:17 PM
Decision-makers often talk of “low hanging fruit” — policies that involve minimal disruption but can yield quick wins. Pharmacare, a program that would see all prescription drug costs covered through a publicly funded system instead of out-of-pocket, isn’t yet seen as low-hanging fruit but it isn’t as high on the tree as decision-makers might think.
Prescription-drug coverage and costs are major challenges in health care. Canada is the only developed country that offers universal health insurance but not universal prescription-drug coverage. As a result, one in 10 Canadians cannot afford to fill the prescriptions their doctors write, yet Canadians spend more on pharmaceuticals than any other comparable country.
We can meet these pharmaceutical policy challenges by reforming how we pay for and purchase medications — that is, if our governments chose to work together. Unfortunately, co-operation doesn’t always come easy in Canadian public policy.
Canadian Medicare was designed in the 1950s and 1960s as a partnership between federal and provincial governments. They built a universal public-health insurance system in stages, beginning with insurance for hospital and then medical care.
Today, health care has been transformed by pharmaceutical innovations that allow us to treat many conditions that previously required hospitalization. As the population ages and pharmaceutical technologies continue to change, prescription-drug coverage and cost will become ever more important for Canada.
Currently, there is no national standard for drug coverage in Canada. We rely on a patchwork of private and public payers working at odds with each other, and not in the interest of patients.
That patchwork has meant profound inequality — Canadians with a chronic illness could face costs between a few hundred dollars to more than a thousand dollars per year, depending on which province they live in — or no drug costs at all, if they have work-related private drug coverage.
The most obvious way to fix this problem would be to bring prescription drugs under our publicly funded health system, just as we have done for doctors and hospitals.
This approach would not cost Canadians more. In fact, if Canada implemented more rational practices for the way pharmaceuticals are purchased and prescribed, we could pay for the most critical medically necessary prescriptions for every single Canadian at little or no more cost to governments.
How is this possible?
The proof is found in developed countries around the world. From the U.K. to New Zealand to the U.S. Veterans Administration, health-care systems in countries like ours provide comprehensive prescription-drug benefits for the same or less cost per capita as what we spend publicly to cover a fraction of our population.
These other health systems get more for less because of two things. First, they use the purchasing power of a single payer to secure best prices for medicines, and they drive hard bargains for those prices.
The U.K., for example, pays 22 per cent less for brand-name drugs than Canada does — yet it still attracts five times as much pharmaceutical investment on a per-capita basis.
The second thing these countries do is engage prescribers and patients in the task of promoting rational, cost-effective prescription drug use. This improves patient outcomes and reduces demands for other forms of health care, while also keeping drug costs in check.
In the absence of federal leadership, provinces and territories have done their best to pick some of the low-hanging fruit to improve coverage and reduce costs for prescription medicines in Canada.
Provinces are co-operating on generic drug price-setting and brand-name price negotiations more now than ever before.
But better pharmacare for all Canadians will be difficult to achieve without the federal government at the table.
The government of Canada could lead on this issue in a way that no single province or territory can do, by supporting the development of a single national list of drugs to be covered for all Canadians and by harnessing the purchasing power of the whole nation to get the best possible bang for our buck.
Danielle Martin is a physician and vice-president at Women’s College Hospital in Toronto. Steve Morgan is a professor and director of the Centre for Health Services and Policy Research at the University of B.C., and an expert adviser with EvidenceNetwork.ca.
© Copyright Times Colonist